17,994 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Bought by Qsemble Capital Management LP

Qsemble Capital Management LP acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 17,994 shares of the company’s stock, valued at approximately $264,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Davidson Kempner Capital Management LP bought a new stake in shares of Elanco Animal Health during the 2nd quarter worth $839,000. Canada Pension Plan Investment Board bought a new position in Elanco Animal Health in the second quarter valued at about $55,599,000. XTX Topco Ltd bought a new position in Elanco Animal Health in the second quarter valued at about $935,000. SG Capital Management LLC bought a new position in Elanco Animal Health in the first quarter valued at about $4,211,000. Finally, Algert Global LLC raised its position in Elanco Animal Health by 22.6% in the second quarter. Algert Global LLC now owns 262,298 shares of the company’s stock valued at $3,785,000 after purchasing an additional 48,358 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on ELAN. Morgan Stanley downgraded Elanco Animal Health from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $17.00 to $15.00 in a research report on Thursday, September 19th. Barclays increased their target price on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 target price on shares of Elanco Animal Health in a research report on Thursday, September 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $17.14.

Elanco Animal Health Price Performance

Shares of ELAN opened at $13.13 on Thursday. Elanco Animal Health Incorporated has a 1 year low of $11.40 and a 1 year high of $18.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The company has a market capitalization of $6.49 billion, a price-to-earnings ratio of 33.10, a price-to-earnings-growth ratio of 1.40 and a beta of 1.41. The business has a 50-day moving average of $13.66 and a 200-day moving average of $14.69.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period last year, the company earned $0.18 earnings per share. The firm’s revenue was down 3.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.